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INTRODUCTION 
 “Acute pancreatitis is the most terrible of all the calamities that occur in 
connection with the abdominal viscera. The suddenness of its onset, the 
illimitable agony which accompanies it, and the mortality attendant upon 
it, all render it the most formidable of catastrophes” 
                                                                                Lord Moynihan, 1925 
 
Acute pancreatitis is an inflammatory process of the pancreas, with 
variable involvement of peri-pancreatic tissues and remote organ systems. 
In majority of the cases, the disease process is mild, with interstitial 
oedema and therefore leads to recovery within a few days or weeks. On 
the other hand, severe pancreatitis, which is characterized by local or 
systemic complications, is very demanding and associated with severe 
morbidity and even death, in nearly 15-20% of the cases. 
The treatment of acute pancreatitis is not disease-specific, targeting 
underlying pathophysiology. Initial life-saving measures include fluid 
resuscitation and supportive therapy to various organ systems which 
mitigates the concomitant course of the disease process thereby 
decreasing the severity of acute pancreatitis. 
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There has been a paradigm shift in the treatment protocols of acute 
pancreatitis over the past two decades. The management has shifted from 
an early aggressive surgical treatment to a more conservative strategy. 
Interventional treatment is seldom needed in majority of the patients with 
acute pancreatitis. However, interventional treatment in the form of 
percutaneous catheter drainage, open or minimally invasive endoscopic 
necrosectomy is indispensable in certain conditions of severe acute 
pancreatitis. 
In this study, we assess the role of image guided percutaneous catheter 
drainage of peri-pancreatic fluid and necrotic collections in the 
management protocols of severe acute pancreatitis. 
This study was conducted at the Institute of General Surgery, Madras 
Medical College and Rajiv Gandhi Government General Hospital. 
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AIMS AND OBJECTIVES 
AIM 
To assess the role of percutaneous catheter drainage in the management 
of severe acute pancreatitis. 
OBJECTIVES 
 To compare and analyze the outcome of patients with severe acute 
pancreatitis managed by conservative treatment, percutaneous 
catheter drainage and surgical necrosectomy. 
 To compare the role of each management strategy in sterile and 
infected necrotic pancreatitis 
 To study the pros and cons of different treatment groups with 
particular emphasis on the benefits of percutaneous catheter 
drainage.  
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REVIEW OF LITERATURE 
Herophilus of Chalkaidon first described pancreas as early as 300B.C. In 
100 A.D., the organ pancreas (Greek: pan, all; kreas, flesh) was named 
by Rufus of Ephesus. Alberti et al. in 1578 recorded a series of patients 
dying of inflammatory conditions or cancer of the pancreas. In 1889, Fitz 
reported the first classification system for acute pancreatitis. In 1901, 
Opie related gallstones as a causative factor to acute pancreatitis and in 
1917, alcohol was identified as an important causative factor. Hans Chiari 
postulated that intra-pancreatic zymogen activation causes pancreatic 
auto-digestion and is an important factor in the development of acute 
pancreatitis. The link between elevated amylase levels and acute 
pancreatitis was realized in the early part of the 20
th
 century. As for as the 
radiological history is concerned, the pancreas was essentially a 
concealed organ which can only be visualized indirectly by upper GI 
barium swallows and barium meal examination. Abdominal 
ultrasonography was the first investigative modality that allowed direct 
pancreatic imaging. However, imaging of the pancreas developed 
exponentially with the advent of computerized axial tomography of the 
abdomen. The indications for surgical management of severe acute 
pancreatitis has changed over the last few decades. In earlier reports, total 
pancreatectomy was performed which caused unacceptably increased 
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mortality. In the late 19
th
 century, open puncture and drainage became the 
first surgical management for a cyst of the pancreas cyst which was 
probably a pseudopancreaticcyst. The current concept states that, surgery, 
offering removal of the non-viable and necrotic tissue benefits those 
patients. Moreover, surgery is also indicated when the conservative 
management fails to improve the MODS. 
 
ETIOLOGY OF ACUTE PANCREATITIS 
Acute pancreatitis has been attributed to a wide range of causative factors 
such as 
Metabolic:- 
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Alcohol 
Hypercalcemia 
Hyperlipidemia 
Drugs like azathioprine, thiazides, aminosalicylic acid 
Genetic 
Mechanical:- 
Cholelithiasis 
Postoperative 
Pancreatic divisum 
ERCP 
Post traumatic 
Pancreatic tumour 
Ascaris lumbricoides  
Pancreatic ductal bleeding 
Duodenal obstruction 
Vascular:- 
Postoperative (e.g. cardiopulmonary bypass) 
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Atheroembolism 
Polyarteritis nodosa 
Infection:- 
Mumps  
Coxsackie  
Cytomegalovirus 
Cryptococcus 
PATHOLOGY OF ACUTE INFLAMMATION OF PANCREAS 
INITIAL EVENTS 
The main role of acinar cells of the pancreas is the formation and release 
of digestive enzymes in an inactive state. The zymogens released into the 
second part of duodenum include pro-carboxy peptidases A and B, pro-
elastase, trypsinogen, chymo-trypsinogen, and pro-phospholipase A2. 
Inactive precursors, produced in the RER are packed within the golgi 
apparatus to be secreted into the small intestine. The granules are then 
released into the lumen of the acini following its stimulation which are 
collected by the ducts of the pancreas to be secreted into the second part 
of the duodenum where its activation happens. The pro-enzymes are 
activated mainly by trypsin. The 2 important   iso-enzymes of trypsinogen 
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include trypsinogen 1 and trypsinogen 2. In normal individuals, 
trypsinogen 1 is four times more than trypsinogen 2 in the secretions of 
pancreas. The proteolytic breakdown of TAP (trypsinogen-activation 
peptide) results in the activation of trypsinogen. Due to the remarkable 
capacity of proteo and lipolysis, trypsinogen can auto-digest the whole 
pancreatic tissue. The safeguarding strategies of the pancreas include 
intra-cellular transport, production of proteolytic proteins as inactive 
precursors, along with enzymes that prevent the intracellular activation of 
zymogens. The pathophysiology of acute pancreatitis is not fully 
understood. The first stage includes mechanisms (extrapancreatic in 
origin) like gall-stone blockage or alcohol consumption that initiate the 
disease process. The major step causing cellular damage is an enzyme 
from lysosome, namely cathepsin-B which activates trypsinogen. Such an 
irreversible process causes acinar cell dysfunction. The activated 
enzymes cause necrosis when it overflows into the interstitial spaces of 
the pancreas, the retro-peritoneal and peritoneal cavity and into the blood-
stream by proteolytic and lipolytic activity. 
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SECONDARY EVENTS  
The pathophysiology of acute pancreatitis is only partially understood by 
the premature activation of pancreatic enzymes. The next step in the 
pathogenesis is explained by the release of different cytokines and 
chemokines. Conditions like septicemia, polytrauma, reperfusion injury 
closely mimics the pathophysiology of acute pancreatitis although it has 
nothing to do with the release of pancreatic zymogens. Damage to the 
cells of the acini propagates a series of catastrophic events. The first 
safeguarding mechanism includes limiting the area of inflammation. 
Failure of this protective strategy promulgates a cascade of catastrophic 
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events ultimately leading to Systemic Inflammatory Response Syndrome. 
Systemic Inflammatory Response Syndrome eventually boils down to 
acute respiratory response syndrome, hypotension, acute kidney injury 
and Multi Organ Dysfunction Syndrome. Events that trigger progression 
from a contained inflammation to a systemic dysfunction are remarkably 
unclear. 
In conclusion, severe acute pancreatitis progresses from a locally 
controlled pancreatic inflammation to a multi systemic derangement. 
Systemic Inflammatory Response Syndrome is defined as two or more of 
the following, hypo or hyperthermia (<36 or >38°C), tachycardia (>90 
bpm), increased respiratory rate (>20 pm, or CO2 <4.3 kiloPascals), 
leucopenia or leukocytosis (<4x10
3
 or >12x10
3
 cells/dL, or >10 % 
leucoblasts). At the other end of the spectrum, severe acute pancreatitis is 
complicated by a pauci-immune stage popularly known as conteractive 
inflammatory response syndrome. During this stage, the individual is 
more prone for infective process primarily from gut bacteria translocation 
thereby culminating in multiorgan dysfunction syndrome frequently 
complicated by poorly guided surgical intervention. The disease 
pathology is associated with significant hypovolemia primarily due to 
fluid loss into the third space, capillary leak and loss of systemic vascular 
resistance. Hypovolemia leads to anemic, hypoxic hypoxia and 
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hypotensive shock which can cause ischemia of the myocardium, cerebral 
and intestinal circulation and theoretically trigger microbial translocation 
from the gut lumen. All these events culminate in the florid production of 
systemic inflammatory mediators including various cytokines and 
chemokines. It is incompletely understood why only some patients 
progress onto florid forms of the disease while others experience only 
mild disease. 
EPIDEMIOLOGY 
The prevalence of acute pancreatitis in various studies ranges from 12 to 
38 per 100000 population
1
. This variation can be explained by the 
differences in consumption of ethanol and in the prevalence of 
cholelithiasis in various parts of the world. 
In our institution, acute pancreatitis accounts for 4-5% of daily hospital 
admissions in the surgical department. It also accounts for about 28% of 
the patients admitted as „acute abdomen‟. Amongst the causes, alcohol 
accounts for nearly 94% of the cases, with gallstones accounting for 5% 
and post-ERCP, drug-induced pancreatitis and idiopathic causes 
contributing to less than 1%. 
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DEFINITIONS 
ACUTE PANCREATITIS 
Acute reversible inflammatory process of the pancreas with variable 
involvement of peri-pancreatic tissues and/or remote organ systems 
associated with increased serum levels of proteases. It is classified as 
either Interstitial pancreatitis (focal or diffuse pancreatic involvement 
with parenchymal tissue enhancement that might be either homogenous 
or a bit heterogenous on intravenous contrast) or Necrotising pancreatitis 
(diffuse or focal areas of non-enhancing parenchyma along with fat 
necrosis of the peripancreatic tissue. Criteria includes non-enhancing 
pancreas less than 50HU involving 30% or 3 cm of the pancreatic 
parenchyma. 
PERIPANCREATIC FLUID COLLECTION 
Fluid that extravasates out of the pancreas and collects into the lesser sac, 
anterior para-renal spaces and into the para-colic gutters. Can occur both 
in interstitial and necrotizing pancreatitis. 
PSEUDOCYST OF PANCREAS 
Collection of pancreatic secretions covered by granulation tissue wall 
occurring after a latency period of atleast four weeks from the onset of 
acute pancreatitis 
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MILD ACUTE PANCREATITIS 
Pancreatitis that is associated with minimal organ dysfunction and an 
uneventful recovery. 
MODERATELY SEVERE ACUTE PANCREATITIS 
Pancreatitis associated with local complications and transient organ 
failure (< 48 hours) 
SEVERE ACUTE PANCREATITIS 
Pancreatitis associated with persistent organ failure and / or death. Local 
complications includes necrosis, abscess or pseudocyst. Organ failure 
includes shock, pulmonary insufficiency, renal failure or gastrointestinal 
bleeding.  
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DIAGNOSIS 
Diagnosis of pancreatitis is based on clinical features, biochemical 
investigations and imaging studies. 
CLINICAL FEATURES 
The dominant symptoms of pancreatitis include pain in the epigastric 
region, nausea, and vomiting. Typically the pain is located in the 
epigastric or peri-umbilical region, but it may also involve both upper 
quadrants, the lower chest and the lower abdomen. It can have a pleuritic 
component and therefore radiate to one or both the shoulders. The pain is 
described as being knife-like and radiating to the back. Usually abrupt in 
onset, it slowly increases in magnitude to reach a maximum level. The 
pain is usually constant, however it is mitigated by leaning forward or 
lying on one side with the knees drawn upward. The vomiting may lead 
to gastro-esophageal tears popularly known as Mallory-Weiss syndrome 
and upper GI bleeding. Eventhough Ryle‟s tube can temporarily improve 
the symptoms of vomiting and retching, the pain does not fully subside 
even after decompression of the stomach. Dehydration, poor skin turgor, 
tachycardia, hypotension, and dry mucous membranes are the common 
signs seen.  
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PHYSICAL FINDINGS 
The clinical findings depends on the severity of acute pancreatitis. With 
mild disease process, the abdomen may be normal or reveal only mild 
epigastric tenderness. However, with severe pancreatitis, significant 
abdominal distention associated with generalized guarding and abdominal 
rigidity might be present. The nature of the pain need not always correlate 
with the clinical findings or the extent of pancreatic inflammation. 
Patients are frequently noted to be rolling or moving around to find a 
more comfortable position which apparently decreases their abdominal 
pain and this might help differentiate patients with a perforated hollow 
viscus who often remain motionless because even the slightest of 
movements deteriorates their abdominal pain. Patients with severe 
pancreatitis usually appear anxious and morbid. Hyperthermia, usually 
recognized, is due to the release of pro-inflammatory cytokines and 
chemokines, from the inflamed pancreas. Hypovolemia can cause 
hypotension, tachycardia and tachypnea and the dreadful triad of acidosis, 
hypothermia and coagulopathy can be fatal. Other findings include 
collapsed neck veins, dry skin, and diminished subcutaneous elasticity 
and dry mucous membranes. Abdominal pain makes breathing difficult 
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which leads to diminished breath sounds in the lower lung fields and 
subsequent atelectasis may be present. 
A pleural effusion is seen commonly on the left side but may involve the 
right side in extensive pathology involving the pancreatic head. Patients 
with severe pancreatitis frequently develop adult respiratory distress 
syndrome and not rarely, patients with pancreatitis have altered mental 
status due to the CNS changes induced by alcohol per se, or hypotension, 
hypoxemia and release of toxic cytokines due to the pathophysiology of 
acute pancreatitis. In biliary pancreatitis, jaundice may reflect distal 
common bile duct obstruction by stones, but jaundice can also occur in 
any type of pancreatitis due to the ductal obstruction by the injured 
pancreas or due to cholestasis induced by the severity of the illness itself. 
The abdomen may become distended and tympanitic and bowel sounds 
absent as a result of paralytic ileus. A mass in the epigastric region, 
indicating the inflamed pancreas and the surrounding peri-pancreatic 
collections, can be present. Rarely retroperitoneal hemorrhage seen 
during severe acute pancreatitis can cause Grey Turner's sign (flank 
ecchymoses) or Cullen's sign (peri-umbilical ecchymoses). Occasionally, 
severe AP causes subcutaneous fat necrosis that present as tender 
subcutaneous induration and erythema resembling erythema nodosum. 
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Acute pancreatitis is diagnosed by the presence of two or more of the 
following features namely severe epigastric pain, amylase or lipase levels 
more than 3 times higher than reference level and CECT abdomen 
demonstrating findings of pancreatic inflammation. Computed 
Tomography is not quintessential for the diagnosis of acute pancreatitis as 
in the earlier phase of the disease (within 72 to 96 hrs of the onset of 
disease), a contrast enhanced CT scan often fails to delineate features of 
peri-pancreatic collections and necrosis as the disease process is a 
dynamic one. However, in patients presenting several days after the onset 
of pain in the abdomen, where the serum amylase and lipase levels might 
have become normal or in patients with organ dysfunction of unknown 
etiology, CT scan plays an important role in establishing the diagnosis. 
IMAGING  
The imaging modality at admission should include a chest and an 
abdominal roentgenogram that demonstrates ARDS, pleural effusion and 
free intra-peritoneal air under the diaphragm (which can sometimes be 
misleading as it may be due to the presence of anaerobic gas forming 
organisms). This is usually followed by a trans-abdominal ultrasonogram 
which is very sensitive to detect GB or CBD sludge and the presence of 
cholelithiasis thereby presuming a diagnosis of biliary pancreatitis. 
However, in the absence of gallstones or GB sludge, a dilated CBD (>8 
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mm if the patient is 75 years or younger; >10 mm if the patient is more 
than 75 years) or the elevation of serum ALT greater than 100 U/L and 
ALT level greater than AST level strongly suggests that acute pancreatitis 
is of biliary origin. These levels provide good guidance for the diagnosis 
of biliary pancreatitis but must be stressed that they are not absolute 
cutoff points. If the etiology still remains elusive, then EUS can be used 
to detect cholelithiasis, GB and CBD sludge. Contrast enhanced CT is 
often used to demonstrate peri-pancreatic fluid collections and pancreatic 
parenchymal or peri-pancreatic fat necrosis. A contrast enhanced CT scan 
has to be done in patients who fail to improve even after seven to ten days 
after the onset of symptoms. The terminology for describing pathologic 
changes in and around the pancreas has seen numerous variations in the 
revised Atlanta classification. A common mistake while reporting peri-
pancreatic collections is to refer it as „pseudocyst’ for a homogeneous 
peri-pancreatic fluid collection that contains fluid and considerable 
amounts of necrotic pancreas. This pitfall arises as the CECT fails to 
discriminate solid necrotic components within a collection that is 
predominantly fluid.  MRI or USG abdomen can circumvent this by 
means of demonstrating the presence or absence of necrosis in such 
apparently homogenous collections. The absence of necrosis is a 
necessity to be called a „pseudocyst‟.   
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SEVERITY CLASSIFICATION 
The updated Atlanta classification overcomes the shortcomings of its 
predecessor published in 1992 due to the improved understanding of the 
pathophysiology of acute pancreatitis, and it includes, a sub-division into 
three types such as mild, moderately severe and severe acute pancreatitis. 
In the early phase of the disease process, this category is dependent on 
clinical parameters, and in the following period, the other subdivision is 
dependent on a combination of clinical parameters as well as 
morphologic complications which increase in-patient hospital stay, and 
necessitating active surgical, radiological or endoscopic intervention and 
supportive management namely, the requirement for vasopressors, 
mechanical ventilation, or renal replacement therapy. The terms „severe‟ 
and „necrotizing‟ pancreatitis do not fully overlap. Necrotizing 
pancreatitis is defined as the presence of parenchymal necrosis or peri-
pancreatic fat necrosis. The updated classification includes peri-
pancreatic necrosis only (i.e., without necrosis of the pancreatic 
parenchyma) in the category of necrotizing pancreatitis. Edematous 
(interstitial) pancreatitis usually runs a mild clinical course, but a few of 
them suffer a fulminant course and die within 2 to 5 days and these 
patients clearly have severe pancreatitis, but are not classified as 
necrotizing one. 
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The clinical course of pancreatitis is extremely haphazard and it defies 
prediction. It may range from complete recovery within a few days to 
SIRS and MODS and mortality within a few hours or days. Though 
several predictive scores have been published to guide physicians in the 
initial treatment and the level of observation required in each individual, 
their value in everyday clinical practice is limited. If an individual meets 
a cutoff value of a particular predictive score, it only means that he can at 
that stage of the disease process, be classified as having „predicted severe 
pancreatitis‟. The clinical value however, is limited, as the subset of 
patients truly progressing to severe acute pancreatitis (positive predictive 
value) is anywhere between 50% and 70%. However, the predictive 
scores also have a negative predictive value ranging between 85% and 
90% and therefore are most useful in excluding patients at risk for severe 
pancreatitis, because of the fact that, patients with mild form of acute 
pancreatitis carry a 10% to 15% risk of developing the severe acute 
pancreatitis. 
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BISAP SCORE 
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APACHE II SCORE 
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MODIFIED BALTHAZAR – CT SEVERITY INDEX 
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The following table depicts the commonly performed predictive scoring 
systems in acute pancreatitis. Also included is their cutoff value in 
predicting acute severe pancreatitis 
    PREDICTIVE 
SCORE  
              CUTOFF 
Modified Glasgow (or 
Imrie) 
≥3 in first 48 hours 
APACHE II ≥8 in first 24 hours 
BISAP ≥3 in first 24 hours 
Ranson ≥3 in first 48 hours 
C reactive protein >150 U/L in the first 72 
hours 
BUN during admission >60 millimol/L 
 
USUAL COURSE OF THE DISEASE PROCESS 
Typically, pancreatitis during the acute stage, demonstrates a biphasic 
course. The initial (1
st
) phase, lasting nearly two weeks is characterized 
by a SIRS (systemic inflammatory response syndrome). The second 
phase, CARS (counteractive anti-inflammatory response syndrome) is 
characterized by a state of immune-suppression
3
. Organ failure in the first 
phase (i.e. SIRS phase) is considered to be due to severe systemic 
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inflammation and is unrelated to infection. On the other hand, organ 
failure in the second phase (i.e. CARS) is occurs due to secondary 
infections, like infected necrosis probably arising due to the translocation 
of bacteria across the gut wall
4
. However, infections, do happen in the 
first (SIRS) phase, but ventilator associated pneumonia and bacteremia 
are the most common types. This finding is based on a study, which 
included a series of patients suffering from severe acute pancreatitis, 
where, it was deduced that these infections (ventilator associated 
pneumonia and septicemia) were most often diagnosed in the first week 
of admission. The respiratory and the cardio-vascular systems are the 
dominant systems involved in organ failure. The gastro-enteric system, 
suffering from a state of low flow and systemic inflammatory response 
syndrome, is difficult to figure out due to vague signs and symptoms, in 
comparison to indicators such as oxygen exchange, blood pressure, and 
urine output, which are well defined. In the first (SIRS) phase, organ 
failure may manifest rarely at admission itself, but is commonly 
elucidated at a median of two days after admission to the hospital. Nearly 
half of the mortality from severe acute pancreatitis is due to multi-organ 
failure and not infected necrosis, contrary to popular belief. This 
statement is strengthened from a series of cohort studies reviewed 
systematically, which concluded that 32% of patients who develop multi-
organ dysfunction eventually succumb to the disease. Death occurring in 
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patients with concurrent multi-organ dysfunction and infected pancreatic 
and peri-pancreatic necrosis was 43%. The clinical course of severe acute 
pancreatitis, being highly variable, there may be a continuum between the 
systemic inflammatory response syndrome and counteractive 
antiinflammatory response syndrome phases. 
The pathophysiology of severe acute pancreatitis is divided into the 
following three stages for a better understanding of the disease process. 
 Week 1: Early onset organ dysfunction, SICU management, 
followed by improvement with supportive measures and continued 
ICU treatment
5
 (Weeks 2 through 3).  
  In the weeks to follow (weeks 3 through 5), clinical deterioration 
occurs. This sequence of events is highly indicative of necrosis 
getting infected. Without early organ failure, clinical stability is 
suddenly complicated by deterioration in weeks 3 through 4 of 
admission. Again, the probability of infected necrosis being the 
underlying etiology of clinical deterioration are high.  
  Early onset organ dysfunction doesn‟t improve, even after 2 to 3 
weeks of conservative treatment in the SICU management. At this 
stage, a fine-needle aspiration of one of the collections can help 
differentiate between persistent systemic inflammatory response 
syndrome and infected necrosis and therefore, determine the need 
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for intervention such as percutaneous drainage or necrosectomy. 
However, if, contrast enhanced CT scan shows air in the necrotic 
components, no further diagnostic procedures are required, and 
intervention to treat the source of infection is necessary. 
TREATMENT OF ACUTE PANCREATITIS 
CONSERVATIVE MANAGEMENT 
First Phase (Systemic Inflammatory Response Syndrome) Treatment: 
1. Adequate fluid resuscitation  
2. Adequate pain relief.  
 A fluid regimen guided by diuretics like frusemide (target output -1 
mL/kilog/hr) is required during the first phase, until there is no 
evidence of organ failure
5
.  
 Careful monitoring and intravenous fluid supplementation in the 
initial twenty four hours of severe acute pancreatitis is most 
important 
 As high as 20 litres of crystalloid solutions might be required. 
However, unrestricted fluid resuscitation may be rapidly fatal 
 A recent RCT from China proved that very high fluid resuscitation 
aimed at keeping hematocrit less than 35% over the first forty eight 
hours was associated with increased mortality. In this initial phase 
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of the disease process, there is no role for any surgical, radiologic 
or endoscopic intervention for the necrotic components. 
Second phase (Counteractive Anti-inflammatory Response Syndrome) 
treatment   
 If the patient does not improve or deteriorates after initial 
stabilization, infection of the pancreatic and peri-pancreatic 
collections should be considered. Fine needle aspiration (FNA) of 
the necrotic collections and subsequent gram staining might be 
considered to confirm this. 
  However, the possibility of false negative results and the risk of 
introducing infection remains a deterrent. Moreover, in cases of 
clinical deterioration, a negative FNA should not deter any kind of 
intervention.  
 A randomized controlled trial based on Sweden demonstrated that 
intervention in individuals with acute necrotizing pancreatitis 
dependent on clinical deterioration rather than on routine fine 
needle aspiration results, indicated, that 92% of patients had 
infected necrosis confirmed at the time of surgical or percutaneous 
catheter intervention.  
 However, presence of gas bubbles in peri pancreatic collections are 
considered as definitive evidence for infected necrosis that would 
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warrant an intervention (either image-guided or surgical) and fine 
needle aspiration is not indicated. 
PREVENTION OF INFECTION  
 In patients with acute severe pancreatitis, various prophylactic 
regimens have been explored for infection prevention because of 
its association with high mortality. Intestinal bacteria are 
considered responsible for the source of these infections and the 
present understanding is that these pathogens pass through the 
mucosal barrier in the first twenty four hours of disease process.  
 In a recent multicentric trial, of all the infections diagnosed during 
the course of acute severe pancreatitis, usually, a septicemia or 
VAP was diagnosed at a median of eight days after the onset of 
epigastric pain, in the first instance.  
 Infection of necrotic components was only deducted at a median of 
twenty-six days. Mortality from each infection including 
pneumonia and bacteremia was thirty percent 
 Bacteremia (due to any cause) increased the risk of infection of 
pancreatic and peri pancreatic necrotic components from anywhere 
between 38% and 65%. This finding was strengthened in 
multivariate analysis which, demonstrated that persistent organ 
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failure (odds ratio 18) and bacteremia (odds ratio 3.4) were the 
strongest predictors of mortality due to severe acute pancreatitis 
  Systemic IV antibiotics, early enteral feeding (oral or nasojejunal), 
selective bowel decontamination, and probiotics have been 
attempted to decrease the infectivity rates.  
 Early enteral feeding is predicted to reduce small bowel microbial 
over-growth and to improve intestinal mucosal barrier function, 
thereby reducing bacterial translocation and subsequent infectious 
complications
7, 8
. A recent RCT by Daniel Bimmler et al. stated 
that, in patients with mild pancreatitis, enteral feeding can be 
started on the day of admission or the next day itself. In predicted 
severe acute pancreatitis, early enteral nutrition by nasojejunal 
(Freka tube) feeding tube within a span of 3 days can be started, if 
the patient cannot tolerate an oral diet
9
.  
 A recent meta-analysis confirmed that, in individuals diagnosed as 
severe acute pancreatitis, early enteral feeding decreases both 
infections complications and mortality when compared with TPN.  
  There is not enough evidence to recommend between various 
enteral nutrition formulations, including glutamine 
supplementation.  
 The best mode for administering enteral feeding via a nasogastric 
or a nasojejunal Freka tube is not universally accepted. Two RCTs, 
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each including nearly eighty cases did not find any difference in 
compliance for feeding and complications between nasogastric and 
nasojejunal routes
8
. These studies also failed to show relevant 
differences regarding various complication rates, such as vomiting, 
aspiration etc. 
Systemic Antibiotics: 
 Several reports have stressed the requirement for antibiotic 
prophylaxis in lowering the problems arising due to infections 
in acute severe pancreatitis. The initial trials showed somewhat 
positive effects. In the recent years, however, placebo controlled 
trials have failed to show a reduction of infections 
complications and mortality. A multicentric study from 
Germany demonstrated an increased prevalence of antibiotic 
resistance and a rise of fungal infections
10, 11
.  
 As a result, based on current evidence, there is no role for the 
routine prophylactic use of systemic intravenous antibiotics.  
Selective Bowel Decontamination: 
 As the intestine is postulated to be the source of bacterial flora for 
the infectious complications in acute severe pancreatitis, it is only a 
rational approach to administer enteral antibiotics. 
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  However, only one randomized control trial studied the efficacy of 
Selective Bowel Decontamination in acute severe pancreatitis and 
compared the effect of enteral antibiotics such as norfloxacin, 
colistin and amphotericin versus placebo
12
. A decrease in death 
rates in the Selective Bowel Decontamination group, primarily due 
to a decrease of gram(-) bacteria of necrotic components was 
found
13
. However, this trial has not been reproduced, and this SBD 
strategy has not been universally accepted. However the collected 
material indicates that the idea of early interventional treatment in 
the wide spectrum of the disease process involving enteric 
microbial overgrowth, mucosal breakdown leading to translocation 
of gut microbia and subsequent septicemia warrants detailed study.  
Pro-biotics: 
 Many multicentric studies have deduced that prophylactic 
administration of pro-biotics can decrease the complications 
arising due to infections in pancreas and liver surgery. 
 A positive effect of prophylactic pro-biotics use in severe acute 
pancreatitis is shown in 2 randomized control trials from 
Europe. On a contrast note, based on a pro-biotics trial in 
Holland, it was demonstrated that, no benefit was gained in 
individuals with severe acute pancreatitis but a 2.5fold higher 
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mortality rate occurred in the individuals receiving probiotics
13
. 
Hence, no proper guideline exists at this point of time, despite 
several follow up studies, clinically and experimentally. 
Therefore, at this point of time, prophylactic enteral probiotics 
are not indicated in cases with predicted acute severe 
pancreatitis. 
INTERVENTIONAL TREATMENT  
First Phase (Systemic Inflammatory Response Syndrome) Treatment 
 Intervention in the first phase of severe acute pancreatitis aims at 
managing acute life-threatening organ dysfunction and prevention 
of further deterioration. As per existing evidence, the only method 
to prevent further deterioration in acute pancreatitis is Endoscopic 
Retrograde Cholangio Pancreatography -ERCP and 
sphincterotomy, even though its exact place in the management 
armamentarium is yet to be established
18, 19
.  
 In 1989, a trial on early surgical necrosectomy, in first phase of the 
disease process, was performed, where, „early‟ surgical treatment 
within seventy-two hours of the onset of abdominal pain was 
compared with „late‟ operation after twelve days. However, the 
study group prematurely terminated the trial due to a much higher 
(though statistically insignificant) mortality rates for „early‟ 
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surgical intervention group (58% vs. 27%). In accordance with this 
trial, early surgical intervention to debride necrotic components 
was essentially given up
14
.  
 It was universally accepted that in the initial stage of the disease 
process, the pathophysiology is dominated by systemic 
inflammatory responses rather than by the presence or absence of 
infection of necrosis. Therefore, there is no apparent benefit is to 
be expected from early surgical intervention, if removal of infected 
necrosis is the sole indication for surgery
16, 17
. 
 Indications for Acute Interventions: 
 The following complications form the basis for early surgical 
intervention. They are,  
1. Abdominal compartment syndrome
15
 
     2. Bowel ischemia  
     3. Hollow viscus perforation 
     4. Severe bleeding, not amenable to angiographic coiling.  
 The definition of abdominal compartment syndrome, includes, IAP 
greater than 20 mm of mercury with features of new-onset organ 
dysfunction such as hypotensive shock, decreased urine output, 
respiratory distress, etc.. 
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  Even though the optimum management of ACS is not fully 
standardized, a consensus meeting suggested that percutaneous 
catheter drainage serves as an initial stabilisation method to drain 
intra-abdominal collection, if significant
15
. If PCD failed to lower 
the pressure immediately or if there is no residual fluid to be 
drained, and the syndrome persists, then emergency laparotomy for 
decompression is advised.  
 The pancreas, however, should not be explored at this stage 
because it is very early to drain the necrotic debris in a safe 
manner, and for the disadvantage of contaminating the necrotic 
debris.  
 Early Endoscopic Retrograde Cholangio Pancreatography with 
sphincterotomy in gall stone pancreatitis: The present 
understanding of the pathogenesis of biliary pancreatitis is that a 
gallstone, released from the GB into the CBD, causes transient 
blockage of the ampulla of Vater, thereby leading to obstruction of 
the pancreatic duct and secondary damage to the exocrine cells 
with auto-digestion of the exocrine pancreas due to the 
extravasation of proteases from the pancreatic juice
18, 19
 
 Therefore, early relief by Endoscopic Retrograde Cholangio 
Pancreatography with sphincterotomy should end this process at an 
early stage and mitigate the risk of progression to complications. 
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However, a recent meta-analysis demonstrated that there is no 
overwhelming benefit of routine ERCP with sphincterotomy in 
patients with predicted acute severe biliary pancreatitis in the 
absence of evidence of cholangitis. 
 On this aspect, a recent prospective multi-center trial concluded 
that sphincterotomy via ERCP decreases the severity and halts the 
pathogenesis of the disease process in individuals with severe 
gallstone pancreatitis and cholestasis (arbitrarily defined as 
bilirubin levels >2.3 millig/dL [>40 micromol/L] or age adjusted 
dilated CBD diameter) 
19
.  
Second Phase (Counteractive Anti-inflammatory Response Syndrome) 
Treatment: 
 Management of infected necrosis during this second (CARS) 
phase, the patient experiences a second attack of septicemia, this 
time, occurring due to a secondary contamination of peri-
pancreatic necrosis via translocation of gut microbes.  
 Therefore, documented or suspected infection of pancreatic or peri-
pancreatic necrosis with signs of sepsis is the most accepted 
indication for intervention, either radiologic, endoscopic, or 
surgical.  
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 However, rare requirements for interventional treatment include 
ACS, severe bleeding, GOO, common bile duct obstruction, and 
hollow viscus perforation.  
 Once a decision for interventional treatment is taken, the options 
include laparotomy with necrosectomy, minimal access surgery, 
endoscopic, and image guided procedures.  
 The incidence and advantages of minimal access procedures is 
exponentially increasing. However, its correct position and 
requirement in the treatment algorithm for all these procedures is 
not exactly formulated till date. Our study tries to highlight the role 
of PCD technique in the treatment strategy of this phase of the 
disease process. 
Timing of Intervention: 
 An experienced multi-disciplinary group should help decide 
„which‟, „when‟, and „where‟, a particular procedure must be 
utilized. Postponement of interventional treatment until the 
parenchymal and peri-pancreatic collections become organized 
which occurs about 4 weeks after the onset of disease, is 
beneficial
6, 21
. 
 These so called encapsulated collections are referred to as „walled 
off pancreatic necrosis (WOPN)‟.  In the emergency clinical 
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situations described earlier, encapsulation of the peri-collection 
might not have been completed, but clinical deterioration would 
warrant an emergency intervention 
 Administration of antibiotics to allow for further encapsulation, 
under close guidance of the clinical developments and periodic 
contrast enhanced CT scan, performed at regular intervals, to 
prevent septicemia, is a valid alternative to postpone surgical 
intervention.  
 In the multicentric trial mentioned earlier, necrosectomy by open 
approach was done after a median period of twenty seven days, 
and the fatality rate was 25%. If intervention was performed in the 
first 2 weeks, mortality was 75%.  
 Based on the findings described above, postponement of 
interventional treatment until about four weeks is the preferred 
management strategy. The length of the conservative management 
interval is mainly determined by the completeness of 
encapsulation of peri-pancreatic collections and the clinical 
condition of the patient. This strategy is therefore, only applicable 
to the subset of patients who survive the first phase of systemic 
inflammatory response syndrome and develop infection of 
necrosis with signs of septicemia, in the second phase of 
counteractive inflammatory response syndrome. 
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Types of Intervention 
Percutaneous Catheter Drainage: 
 Percutaneous Catheter Drainage (PCD) using pigtail catheter is the 
least invasive procedure in the treatment of infected pancreatic and 
peri-pancreatic necrosis. This catheter can be placed 
percutaneously through the retroperitoneum (commonly through 
the left flank) or trans-abdominally, but also across the lumen of 
the stomach and/or the small intestine (mostly duodenum), called 
as „trans-luminal‟ approach. 
 A recent systematic review21 suggested that nearly 55% of patients 
with acute severe pancreatitis, percutaneous pigtail catheter 
drainage can be the sole intervention needed for cure. In this 
review, in about 99% of the cases, the procedure was a success 
technically. The pre-operative organ dysfunction was present in 
77% of the patients, and the case fatality rates was 17%.  
 Accordingly, a multicentric trial from the far West such as the 
United States and Canada demonstrated that 25% of the cases with 
infected necrotizing pancreatitis can be solely managed by a PCD 
procedure. 
 Finally, a landmark multicentric trial from Europe concluded that 
PCD is possible in 99% of the cases. In patients who do not 
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improve after adequate drainage and lavage through the catheter, 
necrosectomy should be considered as the obvious alternative. The 
percutaneous pigtail catheter can be used as a roadmap for 
minimally invasive necrosectomy. This two-step approach, PCD as 
the initial step, following which a catheter-guided minimal access 
necrosectomy as the next step, is popularly known as the “step-up” 
approach and is now believed to be the standard of care in patients 
with infected necrosis
6
.  
Minimally Invasive Necrosectomy - The most frequently performed 
minimal access surgery is the VARD procedure known as video-
assisted retroperitoneal debridement
21, 23
.  
 The initial step of this treatment strategy involves placing a left 
sided percutaneous catheter retroperitoneally through the left flank 
if the collection can be reached through this route. The patient is 
positioned supine with the left side up. Using the pigtail catheter as 
a guidance, a 5 to 7 cm incision is made, and the necrotic collection 
is reached. The initial pus and necrosis are removed in a blind 
manner.  
 This is followed by introduction of a zero degree laparoscope to 
remove all the necrosis in reach, under direct vision. Only loosely 
attached necrotic debris are sucked out and lavaged to reduce 
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bleeding risks. It is seldom necessary to get rid of all necrotic 
debris. In contrast to totally percutaneous necrosectomy 
techniques, VARD can help remove large pieces of necrotic 
debris
22
.  
 Generally, in a well-organized necrosis, necrosectomy can be 
performed safely without concomitant risk of hemorrhage. 
Following near-complete debridement, 2 wide bore drains 
(preferably intercostal drains) are kept into the empty cavity, one at 
the deepest point and the other more shallow.  
 In the postoperative setting, continuous lavage using (2L, 4L and 6 
L of) normal saline is performed through the drains in the first 3 
days. 
 In a recent Dutch multicentric RCT, in individuals with 
documented / suspected contamination of necrotic debris, the 
minimally invasive “step-up” approach was studied in comparison 
with primary open necrosectomy. The results were 
overwhelmingly in favor of the “step-up” approach, but there 
wasn‟t any significant difference in case fatality rates6.  
 Carter at al from Glasgow described a totally minimally invasive 
percutaneous retroperitoneal necrosectomy using an operating 
nephroscope. A recent series confirmed a decrease in mortality 
when using this technique compared with historical controls.  
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 Endoscopic Transluminal Necrosectomy: 
 If video-assisted retroperitoneal debridement is technically not 
feasible when the infected necrosis does not reach far enough left, 
then endoscopic necrosectomy either via trans-luminal or trans-
gastric is a good alternative. Since the earlier description of the 
trans-gastric approach by Seifert in 2000, this technique has been 
increasingly adopted universally with success rates ranging from 
80% to 93% and mortality from 0% to 6%
26
.  
 Controlled trials, however, are required, as selection bias may 
influence the results, and in many trials, the rate of infection of the 
necrotic components was low.  
 The advantages, however, are that no abdominal incision is 
required, and subsequently, external pancreatic fistula is a rare 
occurrence, because, an internal fistula to the stomach or 
duodenum, is created. Incisional hernia, often difficult to treat after 
open necrosectomy, can also be avoided. But, this technique is not 
a one-time treatment and the need for repeated, multiple 
procedures to remove sufficient amounts of necrosis is a distinct 
disadvantage as for as the trans-luminal technique is concerned.  
 
 
 
46 
Open Necrosectomy: 
 Before the conclusions of “PANTER” trial were published6, 
primary „early‟ open necrosectomy was considered as the standard 
of care in patients with suspected or confirmed contamination of 
pancreatic necrosis.  
 The commonly performed surgical method of open necrosectomy 
includes laparotomy with placement of a retroperitoneal drainage 
tube following removal of debris mainly the „fluid under pressure‟.  
 Beger’s Lavage – Beger described placement of lavage systems in 
the lesser sac after surgical removal of the necrotic debris and 
lavaging with serially increasing levels (such as 2L, 4L, and 6 L 
per day) of normal saline (0.9%).  
 Lavage serves various purposes including mechanical debridement, 
prevention of tube obstruction and dilution of pancreatic juice. The 
case fatality rate of this procedure is approximately 25%.  
 Yet another technique of open procedures includes „open 
necrosectomy and closed packing’. Here necrotic debris is 
approached via the transverse mesocolon and debridement is 
performed in a blunt manner, with a target to remove all necrotic 
and particulate debris. Subsequently the resultant cavity is packed 
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with gauze-stuffed Penrose drains and its removal is performed on 
a day to day basis. 
 Many surgeons perform an open abdominal approach where 
periodic, scheduled re-laparotomies is performed every 3 to 5 days. 
As the mortality of this procedure is approximately 70%, it is 
encouraged to use this procedure only as a „rescue‟ technique as 
the last resort, when it is technically impossible to close the 
abdomen. 
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MATERIALS AND METHODS 
PLACE OF STUDY: 
 Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai-600003.  
STUDY DESIGN: 
 Observational (prospective) study 
PERIOD OF STUDY: 
 March 2016 to September 2016 
INCLUSION CRITERIA:   
 Patients above 18 years of age admitted in RGGGH with acute 
necrotizing pancreatitis (defined as increase in serum amylase level 
within the first 48 hours, with a threshold of 3 or 4 times the upper 
normal range, and show evidence of pancreatic necrosis on the contrast-
enhanced CT performed between the 48th and 72nd hrs after the onset of 
abdominal pain) and having one of the following conditions, 
(i)Infected necrotic peripancreatitic collections 
(ii)Symptomatic sterile peripancreatitic collections 
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EXCLUSION CRITERIA:   
1. Patients with collections after pancreatic surgery 
2. Patients who underwent treatment for pseudocyst, which is classified 
as a late (>4-6weeks) complication of pancreatitis  
3. Those not willing to participate in the study 
4. Patients below 18 years of age  
5. Patients who are pregnant 
SAMPLE SIZE: 
  35 patients {Sample size N=Z^2P(1-P)/d^2 where 
Z=1.96,P=10%,d=10%} 
PROCEDURE: 
This is a prospective study based on collected of 35 patients with severe 
acute pancreatitis managed at the Institute of General Surgery, Madras 
Medical College  and RGGGH between March 2016 and September 
2016. The diagnosis of acute pancreatitis is done based on clinical 
features, increased serum amylase or lipase levels and imaging criteria. 
The definition of severe acute pancreatitis is in accordance with the 
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modified Atlanta classification as modified Balthazar or CT severity 
index (CTSI) greater than 7. 
On admission, all the cases are resuscitated with intravenous fluids, organ 
dysfunction management, analgesics and antibiotics such as 
imipenem/cilastatin or meropenem and metronidazole administered 
prophylactically. Within three days of admission, early nutritional 
resuscitation was taken care of. The enteral feeding route, whether per-
oral, nasogastric or nasojejunal was decided by the performance status of 
the individual. In accordance with the culture and sensitivity of the drain 
fluid or blood and urine samples, appropriate antibiotics was 
administered. Continuous monitoring of all the cases were done round the 
clock to watch out for potentially life threatening complications like multi 
organ dysfunction and septicemia. Radiological diagnosis using usg of 
abdomen and/or CT was done in a periodic manner to help assess the 
localization or the spread of inflammatory collections and the 
development and delineation of necrosis. 
Supportive treatment was offered to those individuals who showed 
improvement when compared with their status during admission. Those 
cases who developed (i) contaminated peripancreatic collections (ii) 
sterile but symptomatic (abdominal hypertension or compartment 
syndrome) collections (iii) infected necrosis, (iv) progressive organ 
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dysfunction underwent image-guided PCD or surgical necrosectomy. In 
cases with 5cm or greater collections, demonstrating unrelenting 
hyperthermia, elevated leucocytes and progressive organ dysfunction, an 
USG or CT-guided PCD was performed using a 12 Fr pigtail catheter by 
the Seldinger technique via the transperitoneal or retroperitoneal route 
avoiding injury to the bowel and other vital structures. This technique 
was preceded by Vit. K, FFP and platelet supplementation to treat 
coagulopathy, when required. PCD was anchored to drain by gravity and 
NS irrigation was performed when solid necrotic debris was drained or it 
caused blockage of the tube. Periodic ultrasonogram abdomen was 
performed to verify the emptying of the collections and the requirement 
to flush the tube and reposition the same. Periodic contrast enhanced CT 
scans were done, if need be, to monitor the resolution or the progression 
of the disease process and the requirement for surgical necrosectomy. If 
the drain quantity was lower than ten milliliter for 2 days, the PCD was 
removed under ultrasound guidance. PCD success was defined when 
there was reduction in the size of the fluid collections, control of 
septicemia and absence of requirement of surgery. 
Surgery was performed if there was no clinical improvement, worsening 
organ failure in spite of PCD or when the individuals exhibited 
Warshaw‟s theory of un-wellness37. The surgery included open 
necrosectomy and a irrigation and drainage of the lesser sac. The timing 
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of the surgical treatment, no. of days of SICU care, duration of in-patient 
treatment and case fatality rates were noted. 
 
STATISTICAL ANALYSIS 
All the collected data were tabulated on MS Excel sheet. For the 
categorical and continuous data, the calculations were denoted by 
numbers and percentage of the total and mean ± S.D. respectively. 
Student T test and chi-squared tests were performed to calculate the 
continuous and categorical variables respectively using SPSS (Statistical 
Package for Social Science) software. A “P” value < 0.05 was considered 
as a statistically significant result. 
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OBSERVATION AND INFERENCE 
 35 consecutive patients admitted to the Institute of General 
Surgery, RGGGH with severe acute pancreatitis were studied.  
 The etiology of severe acute pancreatitis were as follows, ethanol 
related in 32(91.4%) cases, gallstones in 2(5.7%) cases and 
idiopathic in 1 (2.9%) patient. 
 Male patients constituted 31(88.6%) and females 4(11.4%) of the 
total study group.  
 The age distribution of the patients were as follows- 4(11.4%) of 
age group 20 – 30 years, 13(37.1%) of age group 30 – 40 years, 
12(34.3%) of age group 40 – 50 years, 6(17.1%) of age group 50 – 
60 years. The mean and standard deviation of this age distribution 
was 40.71 ± 9.06.  
 Serum amylase was elevated to more than three or four times the 
normal in 28 (80.0%) whereas lipase levels was increased in 31 
(88.6%) cases.  
 Acute kidney injury as suggested by elevated blood urea and serum 
creatinine levels was present in 6(17.1%) patients and contrast CT 
scans were promptly avoided in these patients. Those patients who 
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underwent CECT abdomen had instances of SAP with a modified 
Balthazar or CT severity index more than seven.  
 
CATEGORIZATION OF PATIENTS 
.  
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 The patients were initially treated in the SICU; based on their 
response to conservative treatment, they were categorized into 3 
divisions: first, patients manageable by SICU treatment alone; 
second, patients who underwent PCD and third, patients who 
underwent primary surgery or surgery due to the non-improvement 
of the conservative and PCD management.  
 Of the 35 patients, 12(34.3%) patients were treated successfully by 
conservative treatment alone (Group A), whereas 18(51.4%) 
patients required PCD (Group B).  
 Out of 18 cases in Group B, 12 patients (66.7%) were treated 
successfully and there was no necessity for surgical management 
(Group B1) whereas 2 (11.1%) patients were operated on (Group 
B2).  
 Group C consisted of patients who underwent primary surgical 
management-5(14.3%) patients.      
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                        Fig.1. CONSERVATIVE MANAGEMENT 
                         
 
         Fig.2. PERCUTANEOUS CATHETER DRAINAGE GROUP 
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                                   Fig.3. USG GUIDED PCD 
           
                                        Fig.4. DRAIN FLUID 
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                   Fig.5. EXTENSIVE NECROSIS WITH MODS 
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                              Fig.6.NECROSECTOMY GROUP   
          
            Fig.7. PCD ACTED AS A BRIDGE TO NECROSECTOMY 
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SEX DISTRIBUTION 
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ETIOLOGY
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AGE DISTRIBUTION 
C.I f x fx x
/
 x-x
/
 (x-x
/
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2
 f(x-x
/
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21-30 4 25 100 40 -15 225 900 
31-40 13 35    455 40 -5 25 325 
41-50 12 45 540 40 5 25 300 
51-60 6 55 330 40 15 225 1350 
 35  1425    2875 
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ORGAN DYSFUNCTION 
 
 
 
 
 
ACUTE KIDNEY 
INJURY 
32% 
HYPOTENSION 
16% 
ARDS   
10% 
PLEURAL EFFUSION 
26% 
COAGULOPATHY 
16% 
ORGAN DYSFUNCTION 
ACUTE KIDNEY INJURY HYPOTENSION ARDS PLEURAL EFFUSION COAGULOPATHY
 
64 
FLORA IDENTIFIED 
Fine needle aspiration and gram staining was performed in those with no 
direct evidence of infection (absence of air inside the necrotic collections) 
and the following results were obtained. 
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 Non-operative strategy of supportive treatment including fluid 
resuscitation, organ system support (including renal replacement 
therapy), pain alleviation and prophylactic antibiotics 
(imipenem/cilastatin or meropenem and metronidazole) was first 
used in 30 (85.7%) patients.  
 12(340.3%) cases were successfully treated by conservative 
management only (Group A) and 18(51.4) cases were treated with 
conservative approach and PCD (Group B).  
 2(16.7%) patients in Group A had organ dysfunction complication 
in the form of acute kidney injury and acute lung injury. 10(83.3%) 
patients in Group A made an uneventful recovery. 2(16.7%) 
patients recovered after renal replacement therapy in the form of 
hemodialysis
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PERCUTANEOUS CATHETER DRAINAGE (GROUP B) 
 18(51.4%) patients underwent ultrasound or CT-guided drainage of 
the peripancreatic collections. 15(83.3%) of these patients were 
successfully managed by PCD drainage alone, whereas 3(16.7%) 
patients did not show consistent improvement with PCD alone and 
hence underwent laparotomy and necrosectomy thereby migrating 
to Group B2.  
 The most common procedure related complications were catheter 
slippage which required repositioning in 2(11.1%) patients. 
 
15(83.3%) 
PCD ALONE 3(16.7%) 
SURGERY BRIDGED BY PCD 
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NECROSECTOMY AND CLOSED LESSER SAC LAVAGE 
(GROUP C) 
 5(14.3%) patients underwent surgical management in the form of 
necrosectomy and closed lesser sac lavage due to a inadequacy of 
conservative management (Group C) and 2(11.1%) image guided 
PCD (Group B2).  
 The main indications for surgical management included infected 
necrotizing pancreatitis in 3(60%) patients, multi-organ 
dysfunction in 1(20%) patient and Warshaw‟s theory of un-
wellness in 1(20%) patient.  
 Progressive multi-organ dysfunction was the main indication for 
the 2(11.1%) patients who underwent surgery after inadequate 
percutaneous catheter drainage (Group B2).  
 There wasn‟t any significant difference between the individuals 
who underwent surgical management primarily or after inadequate 
percutaneous catheter drainage end organ damage (acute kidney 
injury) (P=1.000), acute lung injury (P=0.715) and duration of in-
patient management (P=0.583).  
 Patients in Group B2 had delayed surgical intervention when 
compared to the patients in Group C, however this difference was 
not statistically significant (P=0.133). 
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 The CT severity index among the patients who were first managed 
conservatively (Groups A and B1) and those patients who 
underwent surgical management (Group B2 and Group C) was 
similar and not statistically significant (P=0.185). 
 Instance of acute kidney injury during in-patient stay was 
significantly greater (P=0.008) in the individuals treated by 
surgical management in comparison to those who underwent 
conservative management.  
 The intensive care management in patients managed non-
operatively and those who underwent surgery was in the range of 
4-25 days and 9-35 days and the mean ± standard deviation was 
6.4±7.8 days and 13.7±16.3 days.  
 The hospital stay in non-operated patients and those who 
underwent surgery was in the range of 16-38 days and 17-69 days 
and the mean ± standard deviation was 26±5.4 days and 43.2±11.7 
days.  
 Individuals treated conservatively had a significantly decreased 
SICU period (P=0.002) and subsequently a decreased in-patient 
period (P=0.003).  
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 The overall case fatality rate was in 3(8.6%) patients with 2(5.7%) 
deaths occurring after surgery and 1(2.9%) patient died in the 
Group B due an acute coronary event.  
 Amongst those patients managed by supportive management alone 
there was no mortality. Amongst the operated patients, both the 
deaths occurred in patients primarily operated upon (Group C) and 
none from inadequate percutaneous catheter drainage group (Group 
B2). 
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DISCUSSION 
 Percutaneous catheter drainage not only decreases the necessity of 
surgical management but also reduces the disease severity and the 
development and progression of organ failure.  
 This study shows that PCD was used successfully in 18 (51.4%) of 
the total 35 cases. Of the 18 patients, 15(42.9) patients recovered 
without the need for surgical management and it helped in delaying 
the morbidity of upfront surgery in 2 (11.1%) patients.  
 Freeny32 and colleagues stated that 47% of their cases were 
successfully treated by „PCD alone‟. Moreover less than 25% of 
their cases needed management by surgery.  
 Navalho33 and colleagues reported that percutaneous catheter 
drainage cured 63% of their patients with 33% of their patients 
necessitating necrosectomy after PCD failed to show any clinical, 
biological and radiological improvement.  
 Moertle et al.34 revealed that PCD procedure has the potential to be 
the bridging gap to surgical intervention in seven of their thirteen 
cases with contaminated pancreatic necrosis.  
 This study strengthens their observations. PCD treatment therefore 
can help in stabilizing the individuals for a critical period that 
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could help in postponing a morbid upfront surgery or altogether 
avoiding surgical intervention.  
 However, a study by Rocha et al.36 stated that the use of image 
guided intervention will not benefit patients suffering from 
necrotizing pancreatitis with concomitant organ failure. 
 Bruennler et al.35 reported that PCD done using multiple larger 
bore drainage catheters has the advantage that these drains would 
help perform a guided percutaneous or fistulous tract necrosectomy 
although most of them required subsequent open necrosectomy and 
therefore concluded that large bore drainage has no advantage in 
controlling the septic focus.  
 Moertele32 and colleagues used an average pigtail catheter of 12 Fr 
size with no mortalities. This study uses a 12Fr. Pigtail catheter for 
PCD and is in accordance with the above studies. 
 The complications of PCD include introduction of infection, 
bleeding, perforation of the hollow viscus or other vital structures 
and slippage of the catheter.  
 Bleeding is a rare event except in patients with coagulopathy (as 
indicated by an elevated PT/INR) and is usually due to the disease 
process itself rather than PCD therapy. Arterial pseudo-aneurysms 
is treated by arterial embolization whereas venous bleeding is 
rarely catastrophic.  
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 Fistulization of the hollow viscus could be due to an inadvertent 
bowel injury during catheter insertion but is more commonly due 
to the spread of peri-pancreatic inflammation.  
 Catheter slippage occurred in 2(11.1%) of our patients and image 
guided repositioning was all that was required to tackle this 
complication. 
 A new entrant in the treatment algorithm of SAP is the use of upper 
gastrointestinal endoscopy to drain infected peri-pancreatic 
collections. A recent trial demonstrated a success rate of 80% with 
trans-gastric upper GI endoscopic necrosectomy and a 
complications rate of 26%.  
 Upper GI endoscopy techniques and PCD offer a safe and an 
effective treatment, being a valuable addition to the 
armamentarium of severe acute pancreatitis management. 
 In conclusion, this study reiterates the value of PCD in the 
management of patients with SAP where majority of our cases 
were managed successfully by non-operative strategies, thus 
obviating a morbid upfront surgical management.  
 PCD bridges a critical morbid period and buys an invaluable time 
frame which help the patient stabilize before progression to 
surgical necrosectomy.  
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 Surgical measures are definitely essential in those where the 
disease process could not be tackled by a supportive and 
percutaneous catheter drainage strategy.  
 Thus, a multimodality approach involving conservative treatment, 
percutaneous catheter drainage and timely surgical necrosectomy is 
quintessential in the treatment of individuals with severe acute 
pancreatitis. 
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CONCLUSIONS 
The initial treatment of acute severe pancreatitis has changed from an 
initial surgical management to a more conservative approach of 
supportive care and minimally invasive therapy. This paradigm shift in 
SAP treatment is a result of path-breaking trials made by various 
investigators who concluded that a high case fatality rate occur after early 
surgical management. Amongst all complications, infected pancreatic 
necrosis (IPN) is, by far, the most dreaded and the most severe, 
accounting for a major cause of mortality associated with acute 
pancreatitis. The risk of contamination by bacteria increases with the 
duration of the disease, reaching a peak during the third week with an 
incidence rate of 71%. It is generally accepted that, in IPN, the 
contaminated non-vital „fluid under pressure‟ has to be debrided to 
control septicemia. Also the sterile fluid collections causing symptoms 
such as abdominal compartment syndrome, compression symptoms such 
as jaundice, duodenal obstruction need to be addressed 
Modern treatment algorithms of SAP involves the so-called „„step-up‟‟ 
approach where percutaneous catheter drainage serves as a primary 
stabilizing measure and is often regarded as a temporizing method to 
tackle septicemia and prolong surgery free interval. The next step is the 
minimal access necrosectomy or the traditional open necrosectomy. That 
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said, in well selected patients, PCD with appropriate caliber drains and 
supplementary therapy is all that is required or it acts as a bridge to a 
delayed necrosectomy which significantly has a low morbidity and 
mortality when compared to an early surgery 
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PATIENT DETAILS 
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Presenting complaints : 
Past history: 
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Treatment history: 
 
 
CLINICAL EXAMINATION 
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Chest Xray: 
Abdomen Xray: 
USG Abdomen: 
CECT Abdomen: 
Provisional diagnosis with etiology: 
 TREATMENT GROUP 
Conservative Management (Group A) 
Percutaneous Catheter Drainage (Group B) 
Surgical Management (Group C) 
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POLY-POLYMICROBIAL 
INFORMATION SHEET 
 
TITLE:  “A STUDY OF THE ROLE OF PERCUTANEOUS CATHETER 
DRAINAGE IN THE MANAGEMENT OF ACUTE SEVERE PANCREATITIS” 
Name of Investigator: Dr. J.MOHAMMED FAROOQ.  Name of Participant: 
 
Purpose of Research: To study the role of percutaneous catheter drainage in the 
management of acute necrotizing pancreatitis and to determine the factors influencing 
its clinical success  
 
Study Design: Prospective Observational Study 
Study Procedures: Patient will be subjected to routine investigations, Xray, Usg, 
CECT Abdomen, complete hemogram, percutaneous catheter drainage procedure as 
indicated, and the data analysed  
Possible Risks: No risks to the patient 
Possible benefits 
To patient : A better understanding of their problem so has to devise a plan of 
management which suits their needs. 
To doctor & to other people:  If this study gives positive results, it can help 
determine the role of percutaneous catheter drainage (minimally invasive procedure) 
in the treatment of patients with severe pancreatitis. This will help in providing better 
and complete treatment to other patients in future. 
Confidentiality of the information obtained from you: The privacy of the patients 
in the research will be maintained throughout the study. In the event of any 
publication or presentation resulting from the research, no personally identifiable 
information will be shared 
Can you decide to stop participating in the study: Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to withdraw at 
any time 
How will your decision to not participate in the study affect you: Your decision 
will not result in any loss of benefits to which you are otherwise entitled. 
 
 
 
 
Signature of Investigator                Signature of Participant 
 
Date : 
Place : 
 
  
PATIENT CONSENT FORM 
 
 
 
 
 
 
 
 
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity 
to ask question and all my questions and doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the Ethics 
committee and the regulatory authorities will not need my permission to look at my health 
records, both in respect of current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties or published, unless 
as required under the law. I agree not to restrict the use of any data or results that arise from this 
study. ❏ 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study  
❏ 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests and to undergo treatment ❏ 
Signature/thumb impression 
Patient’s Name and Address:
Signature of Investigator 
Study Investigator’s Name: 
Dr. J, MOHAMMED FAROOQ 
Study Detail : “A STUDY OF THE ROLE OF PERCUTANEOUS 
CATHETER DRAINAGE IN THE MANAGEMENT OF 
ACUTE SEVERE PANCREATITIS” 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
 
MŒî x¥òjš got« 
MŒÉ‹ jiy¥ò 
fLikahd fiza mH‰á nehÆ‰F njhš _ykhf tofhš á»¢irÆ‹ 
gaDilik g‰¿ m¿tj‰fhd MŒî 
MŒî Ãiya« : bghJ mWit á»¢ir¤Jiw, uhé› fhªâ muR 
bghJ kU¤Jtkid, br‹id kU¤Jt¡ fšÿÇ 
br‹id - 3. 
g§F bgWtÇ‹ bga® :       
g§FbgWgtÇ‹ v© : 
g§FbgWgt® ïjid () F¿¡fî« 
........................................ v‹gtuh»a eh‹ ïªj MŒÉ‹ 
Étu§fS« mj‹ neh¡f§fS« KGikahf m¿ªJbfh©nl‹. vdJ 
rªnjf§fŸ mid¤â‰F« jFªj És¡f« mË¡f¥g£lJ. ïªj MŒÉš 
KG Rjªâu¤Jl‹ k‰W« Ra Ãidîl‹ g§FbfhŸs r«kâ¡»nw‹. 
vd¡F És¡f¥g£l Éõa§fis eh‹ òÇªJbfh©L eh‹ vdJ 
r«kj¤ij bjÇÉ¡»nw‹. ï¢Ra x¥òjš got¤ij g‰¿ vd¡F És¡f¥g£lJ. 
ïªj MŒÉid g‰¿a mid¤J jftšfS« vd¡F bjÇÉ¡f¥g£lJ. 
ïªj MŒÉš vdJ cÇik k‰W« g§»id g‰¿ m¿ªJbfh©nl‹. 
ïªj MŒÉš ãwÇ‹ Ã®gªjÄ‹¿ v‹ brhªj ÉU¥g¤â‹ngÇš jh‹ 
g§F bgW»nw‹ k‰W« eh‹ ïªj MuhŒ¢áÆÈUªJ vªneuK« ã‹th§fyh« 
v‹gijí« mjdhš vªj ghâ¥ò« V‰glhJ v‹gijí« eh‹ òÇªJbfh©nl‹. 
ïªj MŒÉš fyªJbfhŸtj‹ _y« v‹Ål« bgw¥gL« jftiy 
MŒths® ï‹°o£ôrdš v¤â¡° fÄ£oÆdÇlnkh, muR ÃWtd¤âlnkh 
njit¥g£lhš g»®ªJbfhŸsyh« vd r«kâ¡»nw‹. 
ïªj MŒÉ‹ Koîfis btËÆL«nghJ vdJ bgaiunah, 
milahs§fisnah btËÆl¥glhJ vd m¿ªJbfh©nl‹. ïªj 
MŒÉ‹ Étu§fis¡ bfh©l jftš jhis¥ bg‰W¡bfh©nl‹. ïªj 
MŒÉ‰fhf ïu¤j¥ gÇnrhjid brŒJbfhŸs r«kâ¡»nw‹. 
ïªj MŒÉš g§nf‰F« bghGJ VnjD« rªnjf« V‰g£lhš, 
clnd MŒthsiu bjhl®òbfhŸs nt©L« vd m¿ªJbfh©nl‹. 
ïªj MŒÉš vd¡F kU¤Jt gÇnrhjid, ïu¤j¥ gÇnrhjid k‰W« 
ïja c£ò MŒî gÇnrhjid  brŒJbfhŸs KG kdJl‹ r«kâ¡»nw‹. 
ï¢Ra x¥òjš got¤âš ifbaG¤âLtj‹ _y« ïâYŸs mid¤J 
Éõa§fS« vd¡F bjËthf És¡f¥g£lJ v‹W bjÇÉ¡»nw‹ v‹W 
òÇªJbfh©nl‹. ï¢Ra x¥òjš got¤â‹ xU efš vd¡F bfhL¡f¥gL« v‹W 
bjÇªJbfh©nl‹. 
 
g§nf‰ghs®/ ghJfhty® ifbah¥g«     njâ: 
 
MŒths® ifbah¥g«       njâ: 
MŒÉš g§nf‰gtU¡fhd jftš m¿¡if 
MŒî jiy¥ò 
fLikahd fiza mH‰á nehÆ‰F njhš _ykhf tofhš á»¢irÆ‹ 
gaDilik g‰¿ m¿tj‰fhd MŒî 
g§FbfhŸgtÇ‹ bga® :  
MŒî brŒgtÇ‹ bga® :  kU.n#.KfkJ ghU¡ 
ïl« : uhé› fhªâ muR bghJ kU¤Jtkid, 
br‹id-600 003. 
ïªj MŒÉ‹ neh¡f« v‹d? 
e« eh£oš fiza mH‰á nehŒ mâfkhf cŸsJ. mj‰F gšntW 
fhuz§fŸ cŸsd. ïªj MŒÉš uhé› fhªâ muR bghJ 
kU¤JtkidÆš fiza mH‰á nehÆ‰F gšntW gÇnrhjidfŸ k‰W« 
á»¢irfŸ mË¡f¥g£L tU»‹wd. ït‰¿š fLikahd fiza mH‰á 
nehÆ‰F njhš _ykhf tofhš á»¢irÆ‹ gaDilikia g‰¿ m¿tnj 
ïªj MŒÉ‹ neh¡fkhF«. nkY« fiza mH‰áÆdhš V‰gL« nehŒ 
E©k§fŸ Ãiwªj k‰W« nehŒ E©k§fŸ m‰w  âu£LfS¡F njhš 
_ykhf tofhš á»¢irÆ‹ Koîfis x¥ãL« MuhŒ¢á. 
MŒî KiwfŸ 
ÉÇthd nehŒ F¿¥òfS«, kU¤Jt gÇnrhjid k‰W« á»¢ir 
nehahËfŸ mt®fŸ r«kj¤â‰F ïz§f brŒa¥g£L mj‹ 
gaDilikfŸ k‰W« gyhgy‹fŸ Muha¥gL«. 
MŒÉdhš k¡fS¡F V‰gL« e‹ikfŸ 
ïªj MŒÉ‹ KoÉš »il¡F« jftšfŸ rKjha¤â‰F 
gaDŸsjhfî«, vâ®fhy¤âš nehahËfS¡F kU¤Jt Ô®thfî« 
mikí«. 
 
j§fËlÄUªJ bgw¥gL« jftšfË‹ e«gf¤j‹ik 
j§fËlÄUªJ bgw¥gL« jftšfŸ ghJfh¡f¥gLtj‰fhd KG 
cÇikí« j§fS¡F c©L. 
ïªj got¤âš ifbah¥gÄLtâ‹ _y«, jh§fŸ j§fis¥ g‰¿a 
Étu§fisí«, MŒî Étu§fisí« MuhŒ¢áahs®, MŒî el¤J« 
Vidnah® tiuKiw xG§F FGÉd® k‰W« r£l¤â‰F c£g£L kUªJ 
f£L¥ghL ïa¡Fe® M»nah® gh®itÆl mDkâ¡»Ö®fŸ. 
ïªj MŒÉš fh£l¥gL« jftšfŸ m¿Éaš ehnsLfËnyh 
m¿Éaš T£l§fËnyh rk®¥ã¡f¥gL« g£r¤âš j§fsJ milahs« 
btË¥gL¤j¥glkh£lhJ. 
ïªj MŒÉš g§nf‰fhkš ïU¥gâdhš V‰gL« ghâ¥ò 
ïªj MŒÉš jh§fŸ g§nf‰f ÉU¥g« bjÇÉ¡fhj ÃiyÆš 
j§fË‹ kU¤Jt® k‰W« kU¤JtkidÆš j§fS¡F cŸs cwÉš vªj 
ghâ¥ò« V‰glhJ. jh§fŸ áw¥ghf ftÅ¡f¥gLå®fŸ. nkY« ïjdhš 
j§fS¡F ïH¥ò VJ« V‰glhJ. 
MŒÉ‹ eLÉš mâÈUªJ Éy»¡bfhŸs Ãid¤jhš 
ïªj MŒÉš g§nf‰gJ j§fË‹ brhªj ÉU¥gnk. nkY« MŒÉ‹ 
eLÉš vªj neu¤âY«, v¡fhuzK« Twhkš Éy»¡bfhŸs j§fS¡F 
KG cÇikí« c©L. ïU¥ãD« MŒÉÈUªJ ÉyFtj‰F K‹ 
MuhŒ¢á FGîl‹ fyªJ Mnyhá¥gJ cfªjJ vd 
gÇªJiu¡f¥gL»‹wJ. 
 
 
MuhŒ¢áahs® ifbah¥g«   g§nf‰ghs® ifbah¥g« 
njâ:       njâ: 
